---
layout: post
title: "Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Draft Guidance for Industry; Extension of Comment Period"
date: 2026-02-05 19:09:33 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-08609
original_published: 2020-04-23 00:00:00 +0000
significance: 8.00
---

# Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Draft Guidance for Industry; Extension of Comment Period

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 23, 2020 00:00 UTC
**Document Number:** 2020-08609

## Summary

The Food and Drug Administration (FDA or Agency) is extending the comment period for the notice of availability entitled "Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Draft Guidance for Industry" that appeared in the Federal Register of January 30, 2020. The Agency is taking this action to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/04/23/2020-08609/interpreting-sameness-of-gene-therapy-products-under-the-orphan-drug-regulations-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2020-08609

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
